Calithera Biosciences (CALA) Tops Q2 EPS by 1c

Calithera Biosciences (NASDAQ: CALA) reported Q2 EPS of ($0.44), $0.01 better than the analyst estimate of ($0.45).

Financial Guidance for 2015

Calithera reiterates its guidance of its cash, cash equivalents and investments to be at least $65 million at the end of 2015, exclusive of any license milestone payments or funds arising from any additional new collaborations or partnerships, equity financings or other new sources.

For earnings history and earnings-related data on Calithera Biosciences (CALA) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP
• Delta Air shares slip despite strong outlook, Melius says